99 related articles for article (PubMed ID: 25842081)
1. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
[TBL] [Abstract][Full Text] [Related]
2. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
Chin Clin Oncol; 2014 Mar; 3(1):. PubMed ID: 25485277
[TBL] [Abstract][Full Text] [Related]
3. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
4. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
5. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
Ohwada S; Morita S
Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
[TBL] [Abstract][Full Text] [Related]
6. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
7. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
8. Marker Sequential Test (MaST) design.
Freidlin B; Korn EL; Gray R
Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
[TBL] [Abstract][Full Text] [Related]
9. A two-stage patient enrichment adaptive design in phase II oncology trials.
Song JX
Contemp Clin Trials; 2014 Jan; 37(1):148-54. PubMed ID: 24342820
[TBL] [Abstract][Full Text] [Related]
10. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
Liu Y; Kairalla JA; Renfro LA
Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
[TBL] [Abstract][Full Text] [Related]
11. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
12. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Jiang W; Freidlin B; Simon R
J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
[TBL] [Abstract][Full Text] [Related]
14. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
[TBL] [Abstract][Full Text] [Related]
15. A review of phase II trial designs for initial marker validation.
Mandrekar SJ; An MW; Sargent DJ
Contemp Clin Trials; 2013 Nov; 36(2):597-604. PubMed ID: 23665336
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
17. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
20. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Karuri SW; Simon R
Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
